No abstract

Experiencing pain in one leg can alter exercise tolerance and neuromuscular fatigue (NMF) responses in the contralateral leg; however, the corticospinal modulations to non-local experimental pain induced by blood flow occlusion remain unknown. In three randomized visits, thirteen male participants performed 25% of isometric maximal voluntary contraction (25%IMVC) to task failure with one leg preceded by (i) 6-min rest (CON), (ii) cycling at 80% of peak power output until task failure with the contralateral leg (CYCL) or (iii) CYCL followed by blood flow occlusion (OCCL) during 25%IMVC. NMF assessments (IMVC, voluntary activation [VA] and potentiated twitch [Qtw]) were performed at baseline and task failure. During the 25%IMVC, transcranial magnetic stimulations were performed to obtain motor evoked potential (MEP), silent period (SP), and short intracortical inhibition (SICI). 25%IMVC was shortest in OCCL (105±50s) and shorter in CYCL (154±68s) than CON (219±105s) (P<0.05). IMVC declined less after OCCL (-24±19%) and CYCL (-27±18%) then CON (-35±11%) (P<0.05). Qtw declined less in OCCL (-40±25%) compared to CYCL (-50±22%) and CON (-50±21%) (P<0.05). VA was similar amongst conditions. MEP and SP increased and SICI decreased throughout the task while SP was longer for OCCL compared to CYC condition (P<0.05). The results suggest that pain in one leg diminishes contralateral limb exercise tolerance and NMF development and modulate corticospinal inhibition in males. Novelty: Pain in one leg diminished MVC and twitch force decline in the contralateral limb Experimental pain induced by blood flow occlusion may modulation corticospinal inhibition of the neural circuitries innervating the contralateral exercise limb.

Anodal transcranial direct current stimulation (tDCS) of the primary motor cortex has been reported to improve isometric exercise performance without changing corticospinal excitability.One possible cause for this may be the previous use of relatively high (2 mA) current intensities, which have inconsistent effects on corticospinal excitability. The present pre-registered study aimed to replicate previously reported ergogenic effects of 2 mA tDCS, and examine whether 1 mA anodal tDCS both improved isometric exercise performance and perceived fatigue, and more reliably altered corticospinal excitability. On three separate occasions, participants performed a sustained submaximal isometric knee extension until failure after receiving either 1 mA, 2 mA or sham anodal tDCS. Corticospinal excitability of the knee extensors was measured using transcranial magnetic stimulation immediately before and after tDCS. Rating of fatigue was recorded throughout the isometric exercise. Neither 1 nor 2 mA tDCS improved exercise performance, or reduced perceived fatigue, compared to sham stimulation. There was also no effect of tDCS on the corticospinal excitability of the knee extensors. We found no effect of tDCS on either exercise performance, perceived fatigue or corticospinal excitability. This study adds to the growing body of literature reporting no ergogenic effect of tDCS. Large preregistered replications of previously reported effects are now required before tDCS can be considered an effective method to improve exercise performance.

No abstract

Physical activity (PA) is recommended for the management of cancer-related fatigue (CRF), yet the evidence is primarily based on interventions delivered during cancer treatment, with no eligibility criterion for fatigue. The objective of this systematic review was to summarize and evaluate the effect of PA on CRF after cancer treatment (i.e. post-cancer fatigue), using randomized trials where fatigue was an eligibility criterion. Data from 19 eligible studies were extracted by two reviewers. An estimated 7% of all trials on PA for CRF include an eligibility criterion for fatigue after cancer treatment. Sixteen studies were included in a random-effects meta-analysis. Based on studies with substantial heterogeneity and high risk of bias, the effect of PA on post-cancer fatigue was modest and variable (Hedge’s g -0.40; p = 0.010; 95% prediction intervals -1.41 to 0.62). Additional transparently reported randomized clinical trials are needed to better understand the benefits of PA for post-cancer fatigue.